Risks versus Benefits of NSAIDs Including Aspirin in Myocarditis: A Review of the Evidence from Animal Studies

Drug Safety

Volumn 26, Issue 13, 2003, Pages 975-981

  Meune, Christophe ^a   Spaulding, Christian ^a   Mahé, Isabelle ^b   Lebon, Pierre ^a   Bergmann, Jean François ^b  

^a René Descartes University ^*  (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; INDOMETACIN; INTERLEUKIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREDNISONE;

CELL DEATH; COXSACKIE VIRUS B3; COXSACKIE VIRUS B4; CYTOTOXICITY; DRUG ANTAGONISM; HEART MUSCLE CELL; HUMAN; MOUSE; MYOCARDITIS; NONHUMAN; PERICARDITIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; COLCHICINE; COXSACKIEVIRUS INFECTIONS; HUMANS; MYOCARDITIS; PERICARDITIS;

EID: 0142248200     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200326130-00005     Document Type: Review

References (40)

1. Zee-Cheng CS, Tsai CC, Palmer DC, et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates and clinical outcome. N Engl J Med 1985; 312: 885-90
2. Aretz HT, Billingham ME, Edwards WE. et al. Myocarditis: a histopathologic definition and classification. Am J Cardiol Pathol 1985; 1: 1-10
3. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past to the future. Circulation 1999; 99: 1091-100
4. Friman G, Wesslén L, Fohlman J, et al. The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J 1995; 16 Suppl. O: 36-41
5. Boccara F, Benhaiem-Sigaux N, Cohen A. Acute myopericarditis after diphteria, tetanus, and polio vaccination. Chest 2001; 120: 671-2
6. Marcolongo R, Russo R, Laveder F, et al. Immunosuppressive therapy prevents recurrent pericarditis. J Am Coll Cardiol 1998; 26: 1276-9
7. Khatib R, Reyes MP, Smith F, et al. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Med Clin 1990; 116: 116-20
8. Khatib R, Reyes MP, Khatib G, et al. Focal ventricular thinning caused by indomethacin in the late phase of coxsackievirus B4 murine myocarditis. Am J Med Sci 1992; 303: 95-8
9. Costanzo-Nordin MR, Reap EA, O'Connell JB, et al. A nonsteroid anti-inflammatory drug exacerbates coxsackie B3 murine myocarditis. J Am Coll Cardiol 1985; 6: 1078-82
10. Rezkalla S, Khatib G, Khatib R. Coxsackievirus B3 myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents. J Lab Clin Med 1986; 107: 393-5
11. Rezkalla S, Khatib R, Khatib G, et al. Effect of indomethacin in the late phase of coxsackievirus myocarditis in a murine model. J Lab Clin Med 1988; 112: 118-21
12. Zhang S, Kodama M, Hanawa H, et al. Effects of cyclosporine, prednisolone and aspirin on rat autoimmune giant cell myocarditis. J Am Coll Cardiol 1993; 21: 1254-60
13. Orine IM, Shand FL. Inhibitors of prostaglandin synthetase block generation of suppressor T-cells induced by concanavalin A. Int J Immunopharmacol 1981; 3: 15-9
14. Kodama M, Matsumoto Y, Fujiwara M, et al. Characteristics of giant cells and factors related to the formation of giant cells in myocarditis. Circ Res 1991; 69: 1042-50
15. Parillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1061-8
16. Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45
17. Mason JW, O'Connel JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333: 269-75
18. Adachi Y, Yasumizu R, Hashimoto F, et al. An autopsy case of giant cell myocarditis probably due to a non-steroidal anti-inflammatory drug. Pathol Int 2001; 51: 113-7
19. Caforio A, McKenna WJ. Recognition and optimum management of myocarditis. Drugs 1996; 52 (4): 515-25
20. Wayne I, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald E, editor. Heart disease: a textbook of cardiocascular medicine. 5th ed. Philadelphia (PA); W.B. Saunders 1997: 1404-61
21. Rheumatic Fever Working Party (RFWP) of the MRC, Great Britain, and the Subcommittee of Principal investigators of the American Council on Rheumatic Fever and Congenital heart Disease, et al. The treatment of acute rheumatic fever in children: a cooperative clinical trial of ACTH, cortisone and aspirin. Circulation 1955; 2: 343-71
22. Albert DA, Harel L, Karrisson T. The treatment of rheumatic carditis: a review and meta-analysis. Medicine 1995; 74: 1-12
23. Arunasalam S, Siegel RJ. Rapid resolution of symptomatic acute pericarditis with ketorolac tromathamine: a parenteral nonsteroidal antiinflammatory agent. Am Heart J 1993; 125: 1455-8
24. Guindo J, Rodriguez de la Serna A, Ramio J, et al. Recurrent pericarditis: relief with colchicine. Circulation 1990; 82: 1117-20
25. Cacoub P, Sbaǐ A, Wechsler B, et al. Efficacy of colchicine in recurrent acute idiopathic pericarditis. Arch Mal Coeur Vaiss 2000; 93: 1511-4
26. Khatib R, Khatib G, Chason JL, et al. Alteration in coxsackievirus B4 heart muscle disease in ICR Swiss mice by anti-thymocyte serum. J Gen Virol 1983; 64: 231-6
27. Khatib R, Chason JL, Silberberg BK, et al. Age dependent pathogenicity of group B coxsackievirus in Swiss-webster mice: infectivity for myocardium and pancreas. J Infect Dis 1980; 141: 394-403
28. Walz-Cicconi MA, Weller TH. Dose related effects of acetyl-salicylic acid on replication of zoster virus in vitro. Proc Natl Acad Sci U S A 1984; 81: 5223-6
29. Leclerc C, Morin A, Deriand E, et al. Inhibition of human IL2 production by MDP and derivates. J Immunol 1984; 133: 1996-2000
30. Cockran FR, Baxter CS. Carrageenan-induced suppression of T-lymphocyte proliferation in the rat: abrogation of suppressor factor production by the prostaglandin synthesis inhibitors, indomethacin and ETYA. Immunobiology 1984; 166: 275-85
31. Kato K, Askenase PW. Reconstitution of an inactive antigen-specific T cell suppressor factor by incubation of the factor with prostaglandins. J Immunol 1984; 133: 2025-31
32. Factro SM, Minase T, Cho S, et al. Microvascular spasm in the cardiomyopathic Syrian hamster: a preventable cause of focal myocardial necrosis. Circulation 1982; 66: 342-54
33. Sole MJ, Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993; 22 Suppl. A: 99A-105A
34. Feldman AM, McNamara D. Myocarditis. N Engl J Med 2000; 343: 1388-98
35. Grumbach IM, Heim A, Pring-Akerblom I, et al. Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol 1999; 54: 83-8
36. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984; 310: 347-52
37. Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharmacol Ther 2000; 67: 530-7
38. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute haemodynamic interaction of aspirin and ticlopidine with enalapril. Circulation 1998; 98: 757-65
39. Mahe I, Meune C, Diemer M, et al. Interaction between aspirin and ACE inhibitors in patients with heart failure. Drugs Saf 2001; 24 (3): 167-82
40. Saxena A. Treatment of rheumatic carditis. Indian J Pediatr 2002; 69: 513-6